导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.76% | 3247/4773 |
| 近一周 | -1.30% | 1022/5458 |
| 近一月 | -1.29% | 1122/5421 |
| 近一季 | 0.77% | 856/5205 |
| 近半年 | -3.04% | 2263/4920 |
| 近一年 | -1.18% | 2917/4361 |
| 近两年 | 31.87% | 2243/2954 |
| 近三年 | 22.68% | 1387/2253 |
| 成立以来 | 96.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.25% 3093/4961 |
-5.29% 3556/5312 |
- - |
- - |
| 2025 | 14.98% 2578/4813 |
-0.69% 2361/3635 |
-0.12% 2820/4076 |
15.91% 2759/4524 |
0.01% 2286/4813 |
| 2024 | 19.61% 513/3463 |
5.72% 337/2808 |
0.79% 543/3014 |
16.27% 1493/3129 |
-3.46% 2354/3463 |
| 2023 | -4.03% 661/2656 |
5.21% 815/2280 |
-1.32% 472/2385 |
-1.69% 564/2515 |
-5.97% 1579/2655 |
| 2022 | -16.63% 497/2207 |
-12.66% 647/1919 |
5.87% 811/2016 |
-11.18% 502/2113 |
1.51% 1242/2208 |
| 2021 | -9.32% 1075/1822 |
-2.09% 579/1255 |
-1.18% 1160/1330 |
-7.64% 1068/1466 |
1.47% 919/1822 |
| 2020 | 34.75% 435/1250 |
-10.02% 738/1028 |
11.79% 716/1067 |
13.17% 343/1164 |
18.38% 94/1184 |
| 2019 | 39.64% 275/1092 |
22.94% 571/739 |
3.10% 60/788 |
3.93% 226/850 |
6.01% 661/918 |
| 2018 | -19.95% 185/834 |
- - |
-6.59% 126/631 |
0.64% 148/660 |
-12.90% 494/682 |
| 2017 | 41.83% 23/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.91% 114/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇丰晋信恒生龙头指数C VS. 长安沪深300非周期A(740101) |